AdipoGen Life Sciences

Pseudolaric acid B

CHF 30.00
In stock
AG-CN2-0083-C100100 µgCHF 30.00
AG-CN2-0083-M0011 mgCHF 90.00
More Information
Product Details
Synonyms Pseudolarix acid B; PLAB; PAB
Product Type Chemical
Properties
Formula

C23H28O8

MW 432.5
CAS 82508-31-4
RTECS KJ4620000
Source/Host Chemicals Isolated from Pseudolarix kaempferi.
Purity Chemicals ≥98% (HPLC)
Appearance White to off-white solid.
Solubility Soluble in DMSO, ethanol, methanol or chloroform.
InChi Key VDGOFNMYZYBUDT-YDRCMHEVSA-N
Smiles [H][C@@]12CC[C@]3(CC=C(CC[C@]13OC(C)=O)C(=O)OC)C(=O)O[C@]2(C)\C=C\C=C(/C)C(O)=O
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage +4°C
Handling Advice Keep cool and dry.
Use/Stability Stable for at least 2 years after receipt when stored at +4°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description
  • Antifungal and antifertility compound [1, 3].
  • Antitumor compound [2, 7-9, 13].
  • PPARα signaling agonist [4].
  • Angiogenesis inhibitor [5, 6, 11].
  • Apoptosis and autophagy inducer [7, 9, 15, 17].
  • Microtubule-destabilizing agent [8, 11].
  • Anti-inflammatory. Inhibits NF-κB and p38 signaling [12, 14].
  • Immunosuppressive [16].
Product References
  1. Pseudolaric Acids from Pseudolarix kaempferi: B.N. Zhou, et al.; Planta Med. 47, 35 (1983)
  2. The cytotoxic principles of Pseudolarix kaempferi: pseudolaric acid-A and -B and related derivatives: D.J. Pan, et al.; Planta Med. 56, 383 (1990)
  3. Antifungal evaluation of pseudolaric acid B, a major constituent of Pseudolarix kaempferi: E. Li, et al.; J. Nat. Prod. 58, 57 (1995)
  4. Pseudolaric acid analogs as a new class of peroxisome proliferator-activated receptor agonists: M.S. Jardat, et al.; Planta Med. 68, 667 (2002)
  5. Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect: W.F. Tan, et al.; Eur. J. Pharmacol. 499, 219 (2004)
  6. Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1alpha by promoting proteasome-mediated degradation: M.H. Li, et al.; Clin. Cancer Res. 10, 8266 (2004)
  7. Pseudolaric acid B induces apoptosis through p53 and Bax/Bcl-2 pathways in human melanoma A375-S2 cells: X.F. Gong, et al.; Arch. Pharm. Res. 28, 68 (2005)
  8. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo: V.K. Wong, et al.; Clin. Cancer Res. 11, 6002 (2005)
  9. Effect of pseudolaric acid B on gastric cancer cells: inhibition of proliferation and induction of apoptosis: K.S. Li, et al.; World J. Gastroenterol. 11, 7555 (2005)
  10. Pseudolarix acid B, a new tubulin-binding agent, inhibits angiogenesis by interacting with a novel binding site on tubulin: Y.G. Tong, et al.; Mol. Pharmacol. 69, 1226 (2006)
  11. Involvement of JNK-initiated p53 accumulation and phosphorylation of p53 in pseudolaric acid B induced cell death: X. Gong, et al.; Exp. Mol. Med. 38, 428 (2006)
  12. Pseudolaric acid B suppresses T lymphocyte activation through inhibition of NF-kappaB signaling pathway and p38 phosphorylation: T. Li, et al.;  J. Cell Biochem. 108, 87 (2009)
  13. Selective inhibition of human leukemia cell growth and induction of cell cycle arrest and apoptosis by pseudolaric acid B: G. Ma, et al.; J. Cancer Res. Clin. Oncol. 136, 1333 (2010)
  14. Pseudolaric acid B inhibits inducible cyclooxygenase-2 expression via downregulation of the NF-κB pathway in HT-29 cells: L. Hou, et al.; J. Cancer Res. Clin. Oncol. 138, 885 (2012)
  15. Pseudolaric acid B induces apoptosis via proteasome-mediated Bcl-2 degradation in hormone-refractory prostate cancer DU145 cells: D. Zhao, et al.; Toxicol. In Vitro 26, 595 (2012)
  16. The Immunosuppressive Activity of Pseudolaric Acid B on T lymphocytes in vitro: N. Wei, et al: Phytother. Res. 27, 980 (2013)
  17. Pseudolaric Acid B Induces Caspase-Dependent Apoptosis and Autophagic Cell Death in Prostate Cancer Cells: J. Tong, et al.; Phytother. Res. 27, 885 (2013)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.